Naringin, a flavonoid glycoside, mainly found in citrus fruits, has attracted considerable attention for its wide range of pharmacological activities, especially its anti cancer properties. Its therapeutic potential is attributed to the ability to induce apoptosis, suppress cell proliferation and suppress metastases in var ious cancer cell lines. However, clinical application of naringin is hampered by its low bioavailability and fast metabolism. Nanotechnology offers a promising solution to these limitations by facilitating the development of nanoparticles loaded with narin gin to improve their bioavailability, stability and targeted delivery to tumor locations. This review investigates the synthesis, characterization and therapeutic effectiveness of naringin nanoparticles in cancer treatment. The incorporation of Narnidin in to nanocarriers such as liposomes, polymer nanoparticles, and dendrimers significantly improves its drugkinetic profile and therapeutic index. These nanocarriers allow the controlled and continuous release of naringin, leading to an increase in tumor tissu e accumulation while minimizing systemic toxicity. Furthermore, naringin nanoparticles exhibit superior cell absorption and biodistribution, leading to an increased anticancer activity compared to free naringin. Key findings from preclinical studies show t hat nanoparticles of naringin induce apoptosis effectively, stop cell cycles, inhibit angiogenesis and reduce tumor growth in different cancer models. Furthermore, the review highlights the potential to combine naringin nanoparticles with conventional chem otherapy to achieve synergistic cancer treatments and overcome drug resistance. Despite these promising results, the translation of naringin nanoparticles from the table to the bed faces several challenges, including large scale production, regulatory barr iers and a comprehensive evaluation of long term safety and efficacy. Future research should focus on optimizing the formulation of nanoparticles, exploring advanced targeting strategies, and conducting rigorous clinical trials.